June 1, 2022
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director,President and Chief Executive Officer

Completion of Payment for the Issuance of New Shares andthe 58th Stock Acquisition Rights through Third-party Allotment
TOKYO, Japan, June 1, 2022—SymBio Pharmaceuticals Limited (TSE: 4582) (“SymBio” or the “Company”)
today announced that CVI Investments, Inc. (the “Allottee”) has completed payment to the Company for theissuance of new shares (the “New Shares”) and the 58th stock acquisition rights (the “Stock Acquisition Rights”)
through a third-party allotment pursuant to the transaction approved by the Company’s board of directors on May16, 2022. For further details, please refer to the Company’s press release of May 16, 2022 titled “Notice of theIssuance of New Shares and the 58th Stock Acquisition Rights through Third-party Allotment.”
1. Issuance of New Shares(1)

Date of allotment

June 1, 2022

(2)

Number of shares to be issued

1,000,000 common shares(3)

Issue price¥662 per share(4)

Amount of funding¥662,000,000(5)Increase of capital stock¥331,000,000 (¥331 per share)(6)

Increase of legal capital surplus¥331,000,000 (¥331 per share)(7)

Subscription method

Third-party allotment(8)

Allottee

CVI Investments, Inc.

2. Issuance of the Stock Acquisition Rights(1)

Date of allotment

June 1, 2022

(2)

Number of stock

20,000 units (100 shares per unit)

acquisition rights(3)

Issue priceTotal of ¥13,760,000 (¥688 per unit)(4)

Number of dilutive

2,000,000 sharesshares from theissuance(5)

Amount of funding¥1,583,760,000 (Note)(value of property to becontributed in
exercising the Stock
Acquisition Rights)(6)

Exercise price andExercise price of ¥785

conditions for revising

The exercise price shall not be revised.

the exercise price1

(7)Exercise period

From June 2, 2022 to June 1, 2027

(8)

Method for

Third-party allotment

subscription orallotment(9)

Allottee

CVI Investments, Inc.

(10)

Other terms

The Purchase Agreement stipulates the following.
(1) The issuance of the Stock Acquisition Rights allotted to theaforementioned Allottee is subject to conditions that include the following:1) The representations and warranties made by SymBio in the Purchase
Agreement are accurate in material respects, and the Company has fulfilled
its important pledges.
2) No injunction, etc., has been made against the issuance of the Stock
Acquisition Rights.
3) SymBio’s shares have not been delisted.
4) No events have occurred that could have a material adverse impact onSymBio.
5) SymBio has not omitted to inform the Allottee of undisclosed materialfacts related to the Company.
(2) The transfer of the Stock Acquisition Rights (excluding transfers to Bankof America, J.P. Morgan, Goldman Sachs & Co., and their affiliates fromthe perspective of reducing management costs for the Allottee) shall require
the approval of SymBio’s board of directors. If the Stock Acquisition Rights
are transferred, the rights and obligations of the Allottee will be assumed bythe transferee.
In addition, as outlined in “3. Overview of the Funding Method and Reasonfor Selection, (1) Overview of the Funding Method” and in “7. Reasons forHaving Chosen the Allottee, etc., (5) Lock-up Period, etc.” of the press
release regarding this issuance published on May 16, 2022,the Purchase
Agreement sets out other conditions including with respect to purchase ofthe Stock Acquisition Rights and a lock-up period for the issuance of thenew shares. Please refer to the Company’s press release regarding thisissuance published on May 16, 2022.

(Note) If the Stock Acquisition Rights are not exercised during the exercise period, and SymBio cancels the Stock
Acquisition Rights it has acquired, the amount of funding may be lower than the amount shown.
3. Changes in the number of shares issued and the amount of capital stock as a result of the issuance of the Shares
Total number of shares issued
Before the issuance of Shares(as of May 13, 2022)
Increase due to the issuance ofShares
After the issuance of Shares(Note)

Amount of capital stock

38,553,931 shares

17,196,797 thousand yen

1,000,000 shares

331,000 thousand yen

39,553,931 shares

17,527,797 thousand yen(Note) The total number of shares issued and the amount of capital stock after the issuance of Shares do not include
the increase of shares due to the exercise of stock acquisition rights after May 16, 2022.

2